NCT00965432

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy, Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Seaside Therapeutics, Inc. · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral suspension

Conditions

• Fragile X Syndrome

Interventions

Type	Name	Description
DRUG	STX107	Single dose of an oral suspension

Timeline

• Start date: 2009-09-01
• Primary completion: 2010-02-01
• Completion: 2010-02-01
• First posted: 2009-08-25
• Last updated: 2010-02-08

Locations

1 site across 1 country: United States